首页分享基于CAR

基于CAR

来源：花匠小妙招时间：2024-11-24 11:58

[1] 韩颖,石远凯.淋巴瘤诊断与治疗的十年回顾[J].实用肿瘤杂志.2017,(6).

[2] Zhenguang Wang,Yelei Guo,Weidong Han.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment[J].蛋白质与细胞.2017,(12).DOI:10.1007/s13238-017-0400-z .

[3] 佚名.Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J].中国科学（生命科学）（英文版）.2016,59(5).DOI:10.1007/s11427-016-5023-8 .

[4] Ribas, Antoni,Wolchok, Jedd D..Cancer immunotherapy using checkpoint blockade.[J].科学（上海）.2018,359(6382).1350-1355.

[5] June, Carl H.,O��Connor, Roddy S.,Kawalekar, Omkar U.,等.CAR T cell immunotherapy for human cancer.[J].科学（上海）.2018,359(6382).1361-1365.

[6] Weiss, Tobias,Weller, Michael,Guckenberger, Matthias,等.NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma[J].Cancer research: The official organ of the American Association for Cancer Research, Inc.2018,78(4).1031-1043.DOI:10.1158/0008-5472.CAN-17-1788 .

[7] Dandan, Xu,Guoliang, Jin,Dafei, Chai,等.The development of CAR design for tumor CAR-T cell therapy.[J].Oncotarget.2018,9(17).13991-14004.DOI:10.18632/oncotarget.24179 .

[8] Baixin Ye,Creed M. Stary,Xuejun Li3,等.Engineering chimeric antigen receptor-T cells for cancer treatment.[J].Molecular Cancer.2018.171-16.DOI:10.1186/s12943-018-0814-0 .

[9] Shintaku, I. Peter,Long, Georgina V.,Messina, Jane,等.High response rate to PD-1 blockade in desmoplastic melanomas[J].Nature.2018,553(Jan.18 TN.7688).

[10] Neelapu, S. S.,Locke, F. L.,Bartlett, N. L.,等.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J].The New England journal of medicine.2017,377(26).2531-2544.DOI:10.1056/NEJMoa1707447 .